Hepatitis B Virus Vaccine–Induced Cell-Mediated Immunity Correlates with Humoral Immune Response following Primary Vaccination during Infancy

ImmunoHorizons

Volumn 1, Issue 4, 2017, Pages 42-52

  Gelinas, Laura ^a   Abu Raya, Bahaa ^a   Ruck, Candice ^a   Cai, Bing ^a   Kollmann, Tobias R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85044985267     PISSN: None     EISSN: 25737732     Source Type: Journal    
DOI: 10.4049/immunohorizons.1700015     Document Type: Article

References (49)

1. Shepard, C. W., E. P. Simard, L. Finelli, A. E. Fiore, and B. P. Bell. 2006. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol. Rev. 28: 112–125.
2. Amponsah-Dacosta, E., R. L. Lebelo, J. N. Rakgole, R. J. Burnett, S. G. Selabe, and M. J. Mphahlele. 2014. Evidence for a change in the epidemiology of hepatitis B virus infection after nearly two decades of universal hepatitis B vaccination in South Africa. J. Med. Virol. 86: 918–924.
3. Ott, J. J., G. A. Stevens, J. Groeger, and S. T. Wiersma. 2012. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30: 2212–2219.
4. Hyams, K. C. 1995. Risks of chronicity following acute hepatitis B virus infection: a review. Clin. Infect. Dis. 20: 992–1000.
5. Wong, W. W., G. Woo, E. J. Heathcote, and M. Krahn. 2013. Disease burden of chronic hepatitis B among immigrants in Canada. Can. J. Gastroenterol. 27: 137–147.
6. Dentinger, C. M., B. J. McMahon, J. C. Butler, C. E. Dunaway, C. L. Zanis, L. R. Bulkow, D. L. Bruden, O. V. Nainan, M. L. Khristova, T. W. Hennessy, and A. J. Parkinson. 2005. Persistence of antibody to hepatitis B and protection from disease among Alaska natives immunized at birth. Pediatr. Infect. Dis. J. 24: 786–792.
7. Teoharov, P., A. Kevorkyan, N. Petrova, I. Baltadzhiev, and P. Van Damme. 2013. Immune memory and immune response in children from Bulgaria 5-15 years after primary hepatitis B vaccination. Pediatr. Infect. Dis. J. 32: 51–53.
8. Chaves, S. S., G. Fischer, J. Groeger, P. R. Patel, N. D. Thompson, E. H. Teshale, K. Stevenson, V. M. Yano, G. L. Armstrong, T. Samandari, et al. 2012. Persistence of long-term immunity to hepatitis B among adolescents immunized at birth. Vaccine 30: 1644–1649.
9. van der Sande, M. A., M. Mendy, P. Waight, C. Doherty, S. J. McConkey, A. J. Hall, and H. C. Whittle. 2007. Similar long-term vaccine efficacy of two versus three doses of HBV vaccine in early life. Vaccine 25: 1509–1512.
10. Plotkin, S. A. 2010. Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 17: 1055–1065.
11. Jack, A. D., A. J. Hall, N. Maine, M. Mendy, and H. C. Whittle. 1999. What level of hepatitis B antibody is protective? J. Infect. Dis. 179: 489–492.
12. André, F. E. 1990. Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine 8(Suppl.): S74–S78; discussion S79–80.
13. Mendy, M., I. Peterson, S. Hossin, T. Peto, M. L. Jobarteh, A. Jeng-Barry, M. Sidibeh, A. Jatta, S. E. Moore, A. J. Hall, and H. Whittle. 2013. Observational study of vaccine efficacy 24 years after the start of hepatitis B vaccination in two Gambian villages: no need for a booster dose. PLoS One 8: e58029.
14. Zhu, C. L., P. Liu, T. Chen, Z. Ni, L. L. Lu, F. Huang, J. Lu, Z. Sun, and C. Qu. 2011. Presence of immune memory and immunity to hepatitis B virus in adults after neonatal hepatitis B vaccination. Vaccine 29: 7835–7841.
15. Szmuness, W., C. E. Stevens, E. J. Harley, E. A. Zang, H. J. Alter, P. E. Taylor, A. DeVera, G. T. Chen, and A. Kellner. 1982. Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection. N. Engl. J. Med. 307: 1481–1486.
16. Whittle, H. C., H. Inskip, A. J. Hall, M. Mendy, R. Downes, and S. Hoare. 1991. Vaccination against hepatitis B and protection against chronic viral carriage in the Gambia. Lancet 337: 747–750.
17. Leroux-Roels, G., E. Van Hecke, W. Michielsen, P. Voet, P. Hauser, and J. Pêtre. 1994. Correlation between in vivo humoral and in vitro cellular immune responses following immunization with hepatitis B surface antigen (HBsAg) vaccines. Vaccine 12: 812–818.
18. Larsen, C. E., J. Xu, S. Lee, D. P. Dubey, G. Uko, E. J. Yunis, and C. A. Alper. 2000. Complex cytokine responses to hepatitis B surface antigen and tetanus toxoid in responders, nonresponders and subjects naive to hepatitis B surface antigen. Vaccine 18: 3021–3030.
19. Chedid, M. G., H. Deulofeut, D. E. Yunis, M. L. Lara-Marquez, M. Salazar, R. Deulofeut, Z. Awdeh, C. A. Alper, and E. J. Yunis. 1997. Defect in Th1-like cells of nonresponders to hepatitis B vaccine. Hum. Immunol. 58: 42–51.
20. Goncalves, L., B. Albarran, S. Salmen, L. Borges, H. Fields, H. Montes, A. Soyano, Y. Diaz, and L. Berrueta. 2004. The nonresponse to hepatitis B vaccination is associated with impaired lymphocyte activation. Virology 326: 20–28.
21. Vingerhoets, J., G. Vanham, L. Kestens, G. Penne, G. Leroux-Roels, and P. Gigase. 1994. Deficient T-cell responses in non-responders to hepatitis B vaccination: absence of TH1 cytokine production. Immunol. Lett. 39: 163–168.
22. Jafarzadeh, A., and F. Shokri. 2003. The antibody response to HBs antigen is regulated by coordinated Th1 and Th2 cytokine production in healthy neonates. Clin. Exp. Immunol. 131: 451–456.
23. Velu, V., S. Saravanan, S. Nandakumar, E. M. Shankar, A. Vengatesan, S. S. Jadhav, P. S. Kulkarni, and S. P. Thyagarajan. 2008. Relationship between T-lymphocyte cytokine levels and sero-response to hepatitis B vaccines. World J. Gastroenterol. 14: 3534–3540.
24. Ota, M. O., J. Vekemans, S. E. Schlegel-Haueter, K. Fielding, H. Whittle, P. H. Lambert, K. P. McAdam, C. A. Siegrist, and A. Marchant. 2004. Hepatitis B immunisation induces higher antibody and memory Th2 responses in new-borns than in adults. Vaccine 22: 511–519.
25. Carollo, M., R. Palazzo, M. Bianco, E. Pandolfi, P. Chionne, G. Fedele, A. E. Tozzi, R. Carsetti, L. Romanò, and C. M. Ausiello. 2013. Hepatitis B specific T cell immunity induced by primary vaccination persists independently of the protective serum antibody level. Vaccine 31: 506–513.
26. Jarrosson, L., M. N. Kolopp-Sarda, P. Aguilar, M. C. Béné, M. L. Lepori, M. C. Vignaud, G. C. Faure, and C. Kohler. 2004. Most humoral non-responders to hepatitis B vaccines develop HBV-specific cellular immune responses. Vaccine 22: 3789–3796.
27. Kardar, G. A., M. Jeddi-Tehrani, and F. Shokri. 2002. Diminished Th1 and Th2 cytokine production in healthy adult nonresponders to recombinant hepatitis B vaccine. Scand. J. Immunol. 55: 311–314.
28. Corbett, N. P., D. Blimkie, K. C. Ho, B. Cai, D. P. Sutherland, A. Kallos, J. Crabtree, A. Rein-Weston, P. M. Lavoie, S. E. Turvey, et al. 2010. Ontogeny of Toll-like receptor mediated cytokine responses of human blood mononuclear cells. PLoS One 5: e15041.
29. Blimkie, D., E. S. Fortuno III, H. Yan, P. Cho, K. Ho, S. E. Turvey, A. Marchant, S. Goriely, and T. R. Kollmann. 2011. Variables to be controlled in the assessment of blood innate immune responses to Toll-like receptor stimulation. J. Immunol. Methods 366: 89–99.
30. Dienstag, J. L., B. G. Werner, B. F. Polk, D. R. Snydman, D. E. Craven, R. Platt, C. S. Crumpacker, R. Ouellet-Hellstrom, and G. F. Grady. 1984. Hepatitis B vaccine in health care personnel: safety, immunogenicity, and indicators of efficacy. Ann. Intern. Med. 101: 34–40.
31. Zuckerman, J. N., C. Sabin, F. M. Craig, A. Williams, and A. J. Zuckerman. 1997. Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomised double blind dose-response study. BMJ 314: 329–333.
32. Wiedmann, M., U. G. Liebert, U. Oesen, H. Porst, M. Wiese, S. Schroeder, U. Halm, J. Mössner, and F. Berr. 2000. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C. Hepatology 31: 230–234.
33. Dervisoglu, E., M. Simsek, and A. Yilmaz. 2011. Antibody response following hepatitis B vaccination in peritoneal dialysis patients: does normalized urea clearance matter? Clinics (Sao Paulo) 66: 1559–1562.
34. Young, H. A., and K. J. Hardy. 1995. Role of interferon-gamma in immune cell regulation. J. Leukoc. Biol. 58: 373–381.
35. Böcher, W. O., S. Herzog-Hauff, J. Schlaak, K. H. Meyer zum Büschenfeld, and H. F. Löhr. 1999. Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: stimulation of the in vitro antibody response by interferon gamma. Hepatology 29: 238–244.
36. Phillips, S., S. Chokshi, A. Riva, A. Evans, R. Williams, and N. V. Naoumov. 2010. CD8(+) T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions. J. Immunol. 184: 287–295.
37. Guidotti, L. G., T. Ishikawa, M. V. Hobbs, B. Matzke, R. Schreiber, and F. V. Chisari. 1996. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4: 25–36.
38. Carey, I., and D. Vergani. 2007. The role of viral-specific immune responses on the outcome of chronic hepatitis B (HBV) infection in children: new insights into immunopathology. J. Pediatr. Gastroenterol. Nutr. 45: 15–18.
39. Weihrauch, M. R., M. von Bergwelt-Baildon, M. Kandic, M. Weskott, W. Klamp, J. Rosler, and J. L. Schultze. 2008. T cell responses to hepatitis B surface antigen are detectable in non-vaccinated individuals. World J. Gastroenterol. 14: 2529–2533.
40. Rousset, F., E. Garcia, T. Defrance, C. Péronne, N. Vezzio, D. H. Hsu, R. Kastelein, K. W. Moore, and J. Banchereau. 1992. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc. Natl. Acad. Sci. USA 89: 1890–1893.
41. Vassalli, P. 1992. The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. 10: 411–452.
42. Chen, J., Z. Liang, F. Lu, X. Fang, S. Liu, Y. Zeng, F. Zhu, X. Chen, T. Shen, J. Li, and H. Zhuang. 2011. Toll-like receptors and cytokines/ cytokine receptors polymorphisms associate with non-response to hepatitis B vaccine. Vaccine 29: 706–711.
43. Grzegorzewska, A. E., D. Pajzderski, A. Sowinska, ´ A. Mostowska, and P. P. Jagodzinski. ´ 2013. IL4R and IL13 polymorphic variants and development of antibodies to surface antigen of hepatitis B virus in hemodialysis patients in response to HBV vaccination or infection. Vaccine 31: 1766–1770.
44. Crotty, S. 2011. Follicular helper CD4 T cells (TFH). Annu. Rev. Immunol. 29: 621–663.
45. Kurosaki, T., K. Kometani, and W. Ise. 2015. Memory B cells. Nat. Rev. Immunol. 15: 149–159.
46. McElhaney, J. E., D. Xie, W. D. Hager, M. B. Barry, Y. Wang, A. Kleppinger, C. Ewen, K. P. Kane, and R. C. Bleackley. 2006. T cell responses are better correlates of vaccine protection in the elderly. J. Immunol. 176: 6333–6339.
47. European Consensus Group on Hepatitis B Immunity. 2000. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 355: 561–565.
48. Zuckerman, J. N. 1996. Nonresponse to hepatitis B vaccines and the kinetics of anti-HBs production. J. Med. Virol. 50: 283–288.
49. Jilg, W., M. Schmidt, and F. Deinhardt. 1989. Four-year experience with a recombinant hepatitis B vaccine. Infection 17: 70–76.